Active-matter isomorphs in the size-polydisperse Ornstein-Uhlenbeck Lennard-Jones model.

This paper studies size-polydisperse Lennard-Jones systems described by active Ornstein-Uhlenbeck particle (AOUP) dynamics. The focus is on the existence of isomorphs (curves of invariant structure and dynamics) in the model's three-dimensional phase diagram. Isomorphs are traced out from a single steady-state configuration by means of the configurational-temperature method. Good isomorph invariance of the reduced-unit radial distribution function and the mean-square displacement as a function of time is demonstrated for three uniform-distribution polydispersities,12%, 23%, and 29%. Comparing to active-matter isomorphs generated by the analytical direct-isomorph-check method, the latter have poorer invariance of the structure, but better invariance of the dynamics. We conclude that both methods can be used to quickly get an overview of the phase diagram of polydisperse AOUP models involving a potential-energy function obeying the hidden-scale-invariance property required for isomorph theory to apply.

Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes.

Flucloxacillin is a widely used antibiotic. It is an agonist to the nuclear receptor PXR that regulates the expression of cytochrome P450 (CYP) enzymes. Treatment with flucloxacillin reduces warfarin efficacy and plasma concentrations of tacrolimus, voriconazole, and repaglinide. We conducted a translational study to investigate if flucloxacillin induces CYP enzymes. We also investigated if flucloxacillin induces its own metabolism as an autoinducer. We performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic cocktail study. Twelve healthy adults completed the study. They ingested 1 g flucloxacillin 3 times daily for 31 days, and we assessed the full pharmacokinetics of the Basel cocktail drugs on days 0, 10, and 28, and plasma concentrations of flucloxacillin on days 0, 9, and 27. The 3D spheroid of primary human hepatocytes (PHHs) were exposed to flucloxacillin (concentration range: 0.15-250 µM) for 96 hours. Induction of mRNA expression, protein abundance, and enzyme activity of CYP enzymes were assessed. Flucloxacillin treatment reduced the metabolic ratio of midazolam (CYP3A4), (geometric mean ratio (GMR) 10 days (95% confidence interval (CI)): 0.75 (0.64-0.89)) and (GMR 28 days (95% CI): 0.72 (0.62-0.85)). Plasma concentrations of flucloxacillin did not change during 27 days of treatment. Flucloxacillin caused concentration-dependent induction of CYP3A4 and CYP2B6 (mRNA, protein, and activity), CYP2C9 (mRNA and protein), CYP2C19 (mRNA and activity), and CYP2D6 (activity) in 3D spheroid PHH. In conclusion, flucloxacillin is a weak inducer of CYP3A4, which may lead to clinically relevant drug-drug interactions for some narrow therapeutic range drugs that are substrates of CYP3A4.

Solubility of Iridium and Ruthenium Organometallic Photoredox Catalysts.

Despite the exponential growth of the field of photocatalysis, for reasons that are not entirely clear, these precious photocatalysts are often used in the literature at loadings that exceed their maximum solubility. On an industrial scale, the quantity of any precious metal catalyst can be a substantial financial burden or a sourcing issue, not to mention concerns as to the ecological and earth abundance of these catalysts. We believe that inattention to solubility has made these reactions appear less efficient than they actually are, because much of the photocatalyst remains undissolved. Therefore, the maximum solubilities of iridium and ruthenium centered photocatalysts have been systematically identified in industrially relevant solvents. Further, a literature photocatalytic reaction which our results suggested was beyond the maximum solubility has been revisited, with interesting results.